Today, Brokerages gives Consensus Recommendation of “Buy” to Portola Pharmaceuticals Inc. (PTLA)

Today, Brokerages gives Consensus Recommendation of “Buy” to Portola Pharmaceuticals Inc. (PTLA)

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) has earned a consensus rating of “Buy” from the eight brokerages that are covering the company. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $32.30.

A number of equities analysts recently commented on PTLA shares. Citigroup Inc. raised their price target on shares of Portola Pharmaceuticals from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, October 5th. Morgan Stanley reduced their price objective on shares of Portola Pharmaceuticals from $61.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, August 19th. Cowen and Company reiterated a “buy” rating on shares of Portola Pharmaceuticals in a research note on Thursday, August 18th. Finally, Credit Suisse Group AG reduced their price objective on shares of Portola Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 19th.

Large investors have recently bought and sold shares of the stock. IFP Advisors Inc increased its stake in Portola Pharmaceuticals by 2.0% in the second quarter. IFP Advisors Inc now owns 4,318 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 83 shares during the last quarter. BlackRock Inc. increased its stake in Portola Pharmaceuticals by 59.5% in the second quarter. BlackRock Inc. now owns 5,257 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 1,962 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Portola Pharmaceuticals by 16.9% in the second quarter. Teacher Retirement System of Texas now owns 7,889 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 1,140 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Portola Pharmaceuticals during the second quarter valued at approximately $204,000. Finally, Advisor Group Inc. increased its stake in Portola Pharmaceuticals by 225.7% in the third quarter. Advisor Group Inc. now owns 8,950 shares of the biopharmaceutical company’s stock valued at $204,000 after buying an additional 6,202 shares in the last quarter. Institutional investors own 92.07% of the company’s stock.

Portola Pharmaceuticals (NASDAQ:PTLA) traded up 1.43% during midday trading on Friday, hitting $19.20. 220,054 shares of the company were exchanged. The stock’s market capitalization is $1.09 billion. Portola Pharmaceuticals has a one year low of $15.68 and a one year high of $52.89. The firm’s 50-day moving average price is $19.39 and its 200-day moving average price is $22.92.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by $0.54. Portola Pharmaceuticals had a negative return on equity of 82.19% and a negative net margin of 1,072.67%. The business had revenue of $9.30 million for the quarter, compared to the consensus estimate of $4.10 million. During the same period in the prior year, the business posted ($1.05) earnings per share. Portola Pharmaceuticals’s revenue was up 220.7% compared to the same quarter last year. Equities research analysts anticipate that Portola Pharmaceuticals will post ($4.77) earnings per share for the current year.

Related posts

Leave a Comment